Effect of toremifene in breast cancer patients. Preliminary communication.
Toremifene, an antiestrogenic drug administered at three dose levels (60, 120, and 300 mg/day) was investigated in 17 postmenopausal patients with advanced breast cancer previously treated with hormonal and/or cytostatic therapy. The drug proved to be well tolerated at all dose levels without any serious side effects even on prolonged administration. Neither response nor side effects have shown any dose dependency in this small group of patients.
Hindy
I
I
National Institute of Oncology, Budapest, Hungary.
Juhos
E
E
Szántó
J
J
Számel
I
I
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000648:ultrastructure; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D004967:Estrogens; D005260:Female; D006801:Humans; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000648:ultrastructure; D011960:Receptors, Estrogen / Q000502:physiology; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017312:Toremifene
D004965:Estrogen Antagonists; D004967:Estrogens; D011960:Receptors, Estrogen; D013629:Tamoxifen; D017312:Toremifene